Wolff Wiese Magana LLC Purchases Shares of 592 Axon Enterprise, Inc. (NASDAQ:AXON)

Wolff Wiese Magana LLC acquired a new stake in Axon Enterprise, Inc. (NASDAQ:AXON) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 592 shares of the biotechnology company’s stock, valued at approximately $237,000.

A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Axon Enterprise by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares during the last quarter. Motley Fool Asset Management LLC boosted its position in shares of Axon Enterprise by 238.7% during the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after buying an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. boosted its position in shares of Axon Enterprise by 44.0% during the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock valued at $110,546,000 after buying an additional 114,800 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Axon Enterprise by 13.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock worth $108,496,000 after buying an additional 45,049 shares in the last quarter. Finally, Thrivent Financial for Lutherans raised its position in Axon Enterprise by 1.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company’s stock valued at $79,571,000 after buying an additional 4,365 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday, August 7th. Barclays increased their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Northland Securities boosted their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. JMP Securities increased their price target on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Finally, Jefferies Financial Group initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $365.38.

Insider Buying and Selling at Axon Enterprise

In other news, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now directly owns 4,892 shares of the company’s stock, valued at $1,783,916.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Matthew R. Mcbrady sold 2,000 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the sale, the director now directly owns 4,892 shares in the company, valued at $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the transaction, the director now owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 371,172 shares of company stock valued at $137,000,162 in the last 90 days. 5.70% of the stock is currently owned by company insiders.

Axon Enterprise Trading Down 0.1 %

Shares of Axon Enterprise stock opened at $433.83 on Thursday. The stock has a market capitalization of $32.78 billion, a P/E ratio of 114.47, a P/E/G ratio of 11.74 and a beta of 0.94. Axon Enterprise, Inc. has a 52-week low of $199.29 and a 52-week high of $440.89. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The stock’s 50-day simple moving average is $385.93 and its 200 day simple moving average is $330.03.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.80 earnings per share. As a group, research analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.